[Sustained hematologic response in chronic eosinophilic leukemia with low dose imatinib. Report of one case].

Abstract

We report a 58 year-old-man without comorbid conditions, with a history of two months of weight loss, malaise and headache. His initial laboratory analysis showed leukocytosis of 16,100/mL with 65% eosinophils and an absolute eosinophil count of 10,465/mL. Both bone marrow biopsy and aspirate showed infiltration by mature appearing eosinophils. Treatment was started with hydroxyurea, associated with prednisone without satisfactory decrease in the eosinophil count. Polymerase chain reaction showed the presence of the gene fusion product FIP1L1/PDGFRA. Imatinib therapy was initiated, resulting in a rapid and progressive reduction in the absolute eosinophil count, with normalization at the second week of treatment. The incidence of the myeloproliferative variant causing hypereosinophilic syndrome is rare. However, the dramatic response to imatinib emphasizes the need to study the presence of the fusion product FIP1L1/PDGFRA in all patients with eosinophilia of unknown etiology.

• Authors: Demetrio Torres C, Mauricio Chandía
• Journal: Revista medica de Chile (Rev Med Chil) Vol. 142 Issue 4 Pg. 516-20 (Apr 2014) ISSN: 0717-6163 [Electronic] Chile
• Vernacular Title: Leucemia eosinofílica crónica con respuesta hematológica sostenida tras tratamiento con bajas dosis de imatinib.
• PMID: 25117044 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Benzamides
• Piperazines
• Pyrimidines
• Imatinib Mesylate

Topics

• Antineoplastic Agents (therapeutic use)
• Benzamides (therapeutic use)
• Humans
• Hypereosinophilic Syndrome (drug therapy)
• Imatinib Mesylate
• Leukemia
• Male
• Middle Aged
• Piperazines (therapeutic use)
• Pyrimidines (therapeutic use)
• Treatment Outcome